At a glance
- Originator sanofi-aventis
- Class Antihyperlipidaemics; Quinolines; Small molecules
- Mechanism of Action Squalene synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Alzheimer's disease; Hyperlipidaemia
Most Recent Events
- 25 Feb 2009 No development reported - Preclinical for Alzheimer's disease in France (PO)
- 26 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form Sanofi-Aventis
- 28 Jul 2004 Preclinical trials in Alzheimer's disease in France (PO)